摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-N-boc-氨基-4,4-二甲基戊酸 | 856417-59-9

中文名称
3-N-boc-氨基-4,4-二甲基戊酸
中文别名
Boc-(R,S)-3-氨基-4,4-二甲基戊酸;3-N-BOC-氨基-4,4-二甲基戊酸
英文名称
3-((tert-butoxycarbonyl)amino)-4,4-dimethylpentanoic acid
英文别名
4,4-dimethyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]pentanoic acid
3-N-boc-氨基-4,4-二甲基戊酸化学式
CAS
856417-59-9
化学式
C12H23NO4
mdl
——
分子量
245.319
InChiKey
GJOMHEYOQWPVEZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.2
  • 重原子数:
    17
  • 可旋转键数:
    6
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.83
  • 拓扑面积:
    75.6
  • 氢给体数:
    2
  • 氢受体数:
    4

安全信息

  • 海关编码:
    2924199090

反应信息

点击查看最新优质反应信息

文献信息

  • Urea derivative, process for producing the same, and use
    申请人:Kubo Keiji
    公开号:US20070093501A1
    公开(公告)日:2007-04-26
    The present invention provides a urea derivative or a salt thereof, which is useful as a therapeutic agent for thrombosis. The derivative is represented by Formula (I): wherein Cy is an aromatic hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted; R 1 is a hydrogen atom or a hydrocarbon group which may be substituted; V is —C(O)—, —S(O)—, or —S(O) 2 —; W is —N(R 2 )—, —O—, or a bond (wherein R 2 is a hydrogen atom or a hydrocarbon group which may be substituted); X is alkylene which may be substituted; Y is —C(O)—, —S(O)—, or —S(O) 2 —; Z is a bond, a chain hydrocarbon group which may be substituted, or —N═; ring A is a non-aromatic nitrogen-containing heterocyclic ring which may be substituted; ring B is a nitrogen-containing heterocyclic ring which may be substituted; and [Chemical formula 2] , are each independently a single bond or a double bond; provided that R 1 may be bonded to R 2 to form a non-aromatic nitrogen-containing heterocyclic ring and that R 2 may be bonded to a substituent of X to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted.
    本发明提供一种尿素衍生物或其盐,其作为治疗血栓症的治疗剂是有用的。该衍生物由公式(I)表示:其中,Cy是芳香族羟基烃基或芳香族杂环基,可以被取代;R1是氢原子或可以被取代的碳氢基团;V是-C(O)-,-S(O)-或-S(O)2-;W是-N(R2)-,-O-或键(其中R2是氢原子或可以被取代的碳氢基团);X是可以被取代的烷基;Y是-C(O)-,-S(O)-或-S(O)2-;Z是键,可以被取代的链烃基团或-N═;环A是非芳香族含氮杂环环,可以被取代;环B是含氮杂环环,可以被取代;而[化学式2]都是单键或双键;但是,R1可以与R2连接形成非芳香族含氮杂环环,而R2可以与X的取代基连接形成可以被取代的非芳香族含氮杂环环。
  • CYCLIC UREA AND CARBAMATE INHIBITORS OF 11 BETA-HYDROXYSTEROID DEHYDROGENASE 1
    申请人:Claremon David A.
    公开号:US20100197675A1
    公开(公告)日:2010-08-05
    This invention relates to novel compounds of the Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful for the therapeutic treatment of diseases associated with the modulation or inhibition of 11 β-HSD1 in mammals. The invention further relates to pharmaceutical compositions of the novel compounds and methods for their use in the reduction or control of the production of Cortisol in a cell or the inhibition of the conversion of cortisone to Cortisol in a cell.
    本发明涉及公式(I)的新化合物,其药物可接受的盐和药物组合物,用于治疗与哺乳动物中11β-HSD1调节或抑制相关的疾病。本发明还涉及新化合物的药物组合物和它们在细胞中降低或控制皮质醇的产生或抑制皮质酮转化为皮质醇的方法。
  • UREA DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE
    申请人:Takeda Pharmaceutical Company Limited
    公开号:EP1695961A1
    公开(公告)日:2006-08-30
    The present invention provides a urea derivative or a salt thereof, which is useful as a therapeutic agent for thrombosis. The derivative is represented by Formula (I): [Chemical formula I] wherein Cy is an aromatic hydrocarbon group which may be substituted or an aromatic heterocyclic group which may be substituted; R1 is a hydrogen atom or a hydrocarbon group which may be substituted; V is -C(O)-, -S(O)-, or -S(O)2-; W is -N(R2)-, -O-, or a bond (wherein R2 is a hydrogen atom or a hydrocarbon group which may be substituted); X is alkylene which may be substituted; Y is -C(O)-, -S(O)-, or -S(O)2-; Z is a bond, a chain hydrocarbon group which may be substituted, or -N=; ring A is a non-aromatic nitrogen-containing heterocyclic ring which may be substituted; ring B is a nitrogen-containing heterocyclic ring which may be substituted; and [Chemical formula 2] ------‾ , ------̲ are each independently a single bond or a double bond; provided that R1 may be bonded to R2 to form a non-aromatic nitrogen-containing heterocyclic ring and that R2 may be bonded to a substituent of X to form a non-aromatic nitrogen-containing heterocyclic ring which may be substituted.
    本发明提供了一种脲衍生物或其盐,可用作血栓形成的治疗剂。该衍生物由式(I)表示: [化学式 I] 其中 Cy 是可被取代的芳香烃基团或可被取代的芳香杂环基团;R1 是氢原子或可被取代的烃基团;V 是-C(O)-、-S(O)-或-S(O)2-;W 是-N(R2)-、-O-或键(其中 R2 是氢原子或可被取代的烃基团);X是可被取代的亚烷基;Y是-C(O)-、-S(O)-或-S(O)2-;Z是键、可被取代的链烃基或-N=;环 A是可被取代的非芳香族含氮杂环;环 B是可被取代的含氮杂环;以及 [化学式 2] ------‾ , ------̲ 各自独立地为单键或双键;但 R1 可与 R2 键合形成非芳香族含氮杂环,R2 可与 X 的取代基键合形成可被取代的非芳香族含氮杂环。
  • CYCLIC UREA AND CARBAMATE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1
    申请人:Vitae Pharmaceuticals, Inc.
    公开号:EP2125750A2
    公开(公告)日:2009-12-02
  • US7820673B2
    申请人:——
    公开号:US7820673B2
    公开(公告)日:2010-10-26
查看更多